NeuBase Therapeutics, Inc.
NBSEDelisted May 16, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173281
NeuBase Therapeutics, Inc. was delisted on May 16, 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.
Q2 2024 vs. Q1 2024
How the institutions holding NeuBase Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 18 | 2 | −16 |
| Shares | 393.4K | 16.1K | −377.3K (−95.9%) |
| Value | $177.1K | $4.95K | −$172.1K (−97.2%) |
New holders (1)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Baader Bank INC | 16,089 | $4.95K | 0.00% |
Sold out (17)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| DME Capital Management, LPSuperinvestorGreenlight Capital | 136,350 | $61.3K |
| Renaissance Technologies LLC | 88,229 | $40.0K |
| Point72 Asset Management, L.P. | 62,500 | $28.1K |
| Carnegie Mellon University | 46,970 | $21.1K |
| Vanguard Group Inc | 18,981 | $8.54K |
| Prelude Capital Management, LLC | 15,550 | $7.00K |
| Geode Capital Management, LLC | 15,482 | $6.84K |
| UBS Group AG | 4,056 | $1.82K |
| Tower Research Capital LLC (TRC) | 2,572 | $1.16K |
| Cubist Systematic Strategies, LLC | 1,251 | $563 |
| Bank of America Corp | 804 | $361 |
| First Manhattan Co | 353 | $158 |
| Wells Fargo & Company | 79 | $35 |
| The PNC Financial Services Group, Inc. | 21 | $9 |
| Newbridge Financial Services Group, Inc. | 12 | $5 |
| Morgan Stanley | 9 | $4 |
| Royal Bank of Canada | 153 | $0 |